- Disease State/MOA
- ALK+ mNSCLC Clinical Overview
- Dosing for ALECENSA
- Register for Updates
- Contact a Representative
ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (mNSCLC) as detected by an FDA-approved test.
Interstitial Lung Disease (ILD)/Pneumonitis
Severe Myalgia and Creatine Phosphokinase (CPK) Elevation
Most Common Adverse Reactions
Females and Males of Reproductive Potential
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.